111195-92-7Relevant academic research and scientific papers
Preparation method of sulfonyl amidine with 2-Picolylamine and DMF-DMA as amine sources
-
Paragraph 0074-0075, (2020/09/09)
The invention discloses a preparation method of sulfonyl amidine with 2-Picolylamine and DMF-DMA as amine sources. The method comprises the following steps: reacting sulfonyl chloride with 2-Picolylamine to obtain an intermediate product; and then reacting the intermediate product with DMF-DMA in the presence of a catalyst at a temperature of 60-100 DEG C, then performing cooling to room temperature, extracting the reaction solution with ethyl acetate, performing layering, drying and then concentrating to obtain a target product sulfonyl amidine. According to the method disclosed by the invention, the reaction of secondary sulfonamide and DMF-DMA is realized, and the synthesis path of sulfonyl amidine is expanded. The synthetic reaction is simple in operation, mild in condition and convenient in post-treatment, and the obtained intermediate product and the product are high in purity and yield.
Palladium(II) complexes bearing bidentate pyridyl-sulfonamide ligands: Synthesis and catalytic applications
Dayan, Serkan,?etin, Ahmet,Arslan, N. Burcu,?zpozan, Nilgün Kalaycio?lu,?zdemir, Namik,Dayan, Osman
, p. 748 - 753 (2014/12/11)
New palladium(II) complexes ([Pd(1-5)2], 6-10, (1-5 = bidentate pyridyl-sulfonamide ligands)) were obtained from the reaction between Pd(OAc)2 and bidentate pyridyl-sulfonamide ligands. The synthesized compounds were characterized by
Discovery of CGS 27023A, a non, peptidic, potent, and orally active stromelysin inhibitor that blocks cartilage degradation in rabbits
MacPherson, Lawrence J.,Bayburt, Erol K.,Capparelli, Michael P.,Carroll, Brian J.,Goldstein, Robert,Justice, Michael R.,Zhu, Lijuan,Hu, Shou-Ih,Melton, Richard A.,Fryer, Lynn,Goldberg, Ron L.,Doughty, John R.,Spirito, Salvatore,Blancuzzi, Vincent,Wilson, Doug,O'Byrne, Elizabeth M.,Ganu, Vishwas,Parker, David T.
, p. 2525 - 2532 (2007/10/03)
Structure-activity relationships of a lead hydroxamic acid inhibitor of recombinant human stromelysin were systematically defined by taking advantage of a concise synthesis that allowed diverse functionality to be explored at each position in a template. An ex vivo rat model and an in vivo rabbit model of stromelysin-induced cartilage degradation were used to further optimize these analogs for oral activity and duration of action. The culmination of these modifications resulted in CGS 27023A, a potent, orally active stromelysin inhibitor that blocks the erosion of cartilage matrix.
